44
Participants
Start Date
June 30, 2009
Primary Completion Date
November 30, 2011
Study Completion Date
May 31, 2012
Clofarabine
Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
Department of Pediatrics, Peking University People's Hospital, Beijing
Department of Phase 1 Clinical Trial, Peking University People's Hospital, Beijing
Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
The First Hospital of China Medical University, Shenyang
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY